These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 21763253)

  • 1. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges.
    Bhatia S; Davies SM; Scott Baker K; Pulsipher MA; Hansen JA
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1428-35. PubMed ID: 21763253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
    Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation.
    Atsuta Y; Hirakawa A; Nakasone H; Kurosawa S; Oshima K; Sakai R; Ohashi K; Takahashi S; Mori T; Ozawa Y; Fukuda T; Kanamori H; Morishima Y; Kato K; Yabe H; Sakamaki H; Taniguchi S; Yamashita T;
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1702-1709. PubMed ID: 27246369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.
    Chow EJ; Anderson L; Baker KS; Bhatia S; Guilcher GM; Huang JT; Pelletier W; Perkins JL; Rivard LS; Schechter T; Shah AJ; Wilson KD; Wong K; Grewal SS; Armenian SH; Meacham LR; Mulrooney DA; Castellino SM
    Biol Blood Marrow Transplant; 2016 May; 22(5):782-95. PubMed ID: 26802323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
    Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
    Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases.
    Umeda K; Imai K; Yanagimachi M; Yabe H; Kobayashi M; Takahashi Y; Kajiwara M; Yoshida N; Cho Y; Inoue M; Hashii Y; Atsuta Y; Morio T;
    Int J Hematol; 2020 Jun; 111(6):869-876. PubMed ID: 32052319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.
    Wingard JR; Majhail NS; Brazauskas R; Wang Z; Sobocinski KA; Jacobsohn D; Sorror ML; Horowitz MM; Bolwell B; Rizzo JD; Socié G
    J Clin Oncol; 2011 Jun; 29(16):2230-9. PubMed ID: 21464398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks.
    Dvorak CC; Gracia CR; Sanders JE; Cheng EY; Baker KS; Pulsipher MA; Petryk A
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1725-38. PubMed ID: 22005649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
    Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1327-1334. PubMed ID: 28461213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin.
    Kothari A; Ngwube A; Hayashi R; Murray L; Davis J; Haut P; Loechelt BJ; Shenoy S
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1321-5. PubMed ID: 25840334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
    Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
    Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.
    Phelan R; Im A; Hunter RL; Inamoto Y; Lupo-Stanghellini MT; Rovo A; Badawy SM; Burns L; Eissa H; Murthy HS; Prasad P; Sharma A; Suelzer E; Agrawal V; Aljurf M; Baker K; Basak GW; Buchbinder D; DeFilipp Z; Grkovic LD; Dias A; Einsele H; Eisenberg ML; Epperla N; Farhadfar N; Flatau A; Gale RP; Greinix H; Hamilton BK; Hashmi S; Hematti P; Jamani K; Maharaj D; Murray J; Naik S; Nathan S; Pavletic S; Peric Z; Pulanic D; Ross R; Salonia A; Sanchez-Ortega I; Savani BN; Schechter T; Shah AJ; Smith SM; Snowden JA; Steinberg A; Tremblay D; Vij SC; Walker L; Wolff D; Yared JA; Schoemans H; Tichelli A
    Transplant Cell Ther; 2022 Jun; 28(6):335.e1-335.e17. PubMed ID: 34757220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.
    Admiraal R; van Kesteren C; Jol-van der Zijde CM; Lankester AC; Bierings MB; Egberts TC; van Tol MJ; Knibbe CA; Bredius RG; Boelens JJ
    Lancet Haematol; 2015 May; 2(5):e194-203. PubMed ID: 26688094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties.
    Uderzo C; Pillon M; Corti P; Tridello G; Tana F; Zintl F; Nysom K; Galambrun C; Fagioli F; Varotto S; Messina C; Verdeguer A; Urban C; Faraci M; Dini G; Fedeli S; Tichelli A; Rovelli A; Socié G
    Bone Marrow Transplant; 2007 Jun; 39(11):667-75. PubMed ID: 17401396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
    Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
    Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.
    Nieder ML; McDonald GB; Kida A; Hingorani S; Armenian SH; Cooke KR; Pulsipher MA; Baker KS
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1573-84. PubMed ID: 21963877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report.
    Morton LM; Saber W; Baker KS; Barrett AJ; Bhatia S; Engels EA; Gadalla SM; Kleiner DE; Pavletic S; Burns LJ
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):367-378. PubMed ID: 27634019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.
    Holtan SG; DeFor TE; Lazaryan A; Bejanyan N; Arora M; Brunstein CG; Blazar BR; MacMillan ML; Weisdorf DJ
    Blood; 2015 Feb; 125(8):1333-8. PubMed ID: 25593335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.